arrow
J

Joep Killestein

ms center amsterdam
H指数:62
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Return of Research Results to Participants in Longitudinal Cohort Studies in Health Research: Findings From 24 Cohorts of the Amsterdam Cohort Hub

健康研究中纵向队列研究的结果反馈给参与者:来自阿姆斯特丹队列中心24个队列的研究发现

2026-10-040
OAAI
Anti-CD20 B cell depletion is associated with elevated mucosal-originating circulating regulatory IgA B cells in multiple sclerosis

抗CD20 B细胞耗竭与多发性硬化中黏膜来源的循环调节性IgA B细胞升高相关

2026-07-220
PRE
Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of Ocrelizumab

多发性硬化患者接受奥瑞利珠单抗延长间隔给药后CD19+ B细胞再生的个体差异

2026-07-070
OA
Treatment satisfaction during personalized extended interval dosing of natalizumab in patients with multiple sclerosis

多发性硬化患者个性化延长间隔给药方案下纳武利尤单抗的治疗满意度

2026-07-010
PRE
The practice effect of smartphone-derived cognitive processing speed assessments as a proxy of cognitive functioning in multiple sclerosis

智能手机衍生的认知处理速度评估作为多发性硬化症认知功能代理的实践效应

2026-05-070
OAAI
Enhancing the interpretability of spinal cord atrophy in multiple sclerosis by reducing interindividual variability due to anatomical differences

通过减少由于解剖差异引起的个体间变异性来增强多发性硬化中脊髓萎缩的可解释性

2026-02-010
OAAI
Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria

多发性硬化症的诊断:2024年麦卡唐纳标准的修订

2025-09-170
OA
Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS)

血清神经丝蛋白轻链和胶质纤维酸性蛋白在稳定型多发性硬化(DOT-MS)中停用一线疾病修饰疗法后检测疾病活动的可靠性

2025-07-230
OAAI